TY - JOUR
T1 - Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer
T2 - differences and agreements with European and American guidelines
AU - Groheux, David
AU - Vaz, Sofia C.
AU - Ulaner, Gary A.
AU - Cook, Gary J.R.
AU - Woll, John Patrick Pilkington
AU - Mann, Ritse M.
AU - Poortmans, Philip
AU - Cardoso, Fatima
AU - Jacene, Heather
AU - Graff, Stephanie L.
AU - Rubio, Isabel T.
AU - Peeters, Marie Jeanne Vrancken
AU - Dibble, Elizabeth H.
AU - de Geus-Oei, Lioe Fee
PY - 2024/7
Y1 - 2024/7
N2 - Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Recently, 2-[18F]FDG PET/CT has become indispensable in the care of patients with BC. In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, the Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer [1] is published. This is the first guideline with the nuclear medicine societies’ participation in this topic endorsed by the following relevant societies in this field: the American College of Radiology (ACR), the European Society of Surgical Oncology (ESSO), the European Society for Radiotherapy and Oncology (ESTRO), the European Society of Breast Imaging/European Society of Radiology (EUSOBI/ESR), and the European Society of Breast Cancer Specialists (EUSOMA). In these guidelines, updated information about 2-[18F]FDG PET/CT procedures is summarized, and the current evidence of the role of 2-[18F]FDG PET/CT in the initial staging, assessment of treatment response, and assessment of recurrence in patients with BC is presented and organized into recommendation boxes (and summarized in Table 5 of the EANM/SNMMI guidelines). All recommendations were scored in terms of level of evidence and grade of recommendation, with a percentage of agreement of at least 85% by a group multidisciplinary team of experts. Finally, other developments and future applications are discussed [1].
AB - Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Recently, 2-[18F]FDG PET/CT has become indispensable in the care of patients with BC. In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, the Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer [1] is published. This is the first guideline with the nuclear medicine societies’ participation in this topic endorsed by the following relevant societies in this field: the American College of Radiology (ACR), the European Society of Surgical Oncology (ESSO), the European Society for Radiotherapy and Oncology (ESTRO), the European Society of Breast Imaging/European Society of Radiology (EUSOBI/ESR), and the European Society of Breast Cancer Specialists (EUSOMA). In these guidelines, updated information about 2-[18F]FDG PET/CT procedures is summarized, and the current evidence of the role of 2-[18F]FDG PET/CT in the initial staging, assessment of treatment response, and assessment of recurrence in patients with BC is presented and organized into recommendation boxes (and summarized in Table 5 of the EANM/SNMMI guidelines). All recommendations were scored in terms of level of evidence and grade of recommendation, with a percentage of agreement of at least 85% by a group multidisciplinary team of experts. Finally, other developments and future applications are discussed [1].
KW - n/a OA procedure
UR - https://www.scopus.com/pages/publications/85191998559
U2 - 10.1007/s00259-024-06694-x
DO - 10.1007/s00259-024-06694-x
M3 - Editorial
C2 - 38693453
AN - SCOPUS:85191998559
SN - 1619-7070
VL - 51
SP - 2701
EP - 2705
JO - European journal of nuclear medicine and molecular imaging
JF - European journal of nuclear medicine and molecular imaging
IS - 9
ER -
